Skip to main content
Premium Trial:

Request an Annual Quote

Link Technologies Inks License for PNA's PNA Synthesis Tech

NEW YORK (GenomeWeb News) - Link Technologies has entered a non-exclusive license agreement with PNA Inventor Group that will allow it to manufacture and sell monomers for peptide nucleic acid synthesis worldwide.
 
Link Technologies said that numerous uses for PNAs have been identified or proposed for molecular biology applications, diagnostic assays, and antisense therapies.
 
The company added that it expects PNA-related technologies to account for 10 percent of the global DNA synthesis market by 2010. This market is currently worth $800 million and growing at more than 10 percent per year, the company said.
 
PNAs are oligonucleotide analogs in which the sugar-phosphate backbone of DNA is substituted by a pseudo-peptide backbone. They hybridize to complementary DNA or RNA, but are not degraded by nucleases or proteases, Link Technologies said.
 
Link Technologies said that it will begin offering PNA monomers that are compatible with commercial automated oligonucleotide, peptide, or combinatorial synthesizers, in July.
 
Financial terms of the agreement were not released.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.